Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
25/10/201822:00PR Newswire (US)EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 TrialNASDAQ:REGNRegeneron Pharmaceuticals Inc
22/10/201822:00PR Newswire (US)FDA Approves Asthma Indication for Dupixent® (dupilumab)NASDAQ:REGNRegeneron Pharmaceuticals Inc
20/10/201809:52Dow Jones NewsFDA Approves Asthma Indication for Regeneron and Sanofi's DupixentNASDAQ:REGNRegeneron Pharmaceuticals Inc
20/10/201808:55PR Newswire (US)FDA Approves Asthma Indication for Dupixent® (dupilumab)NASDAQ:REGNRegeneron Pharmaceuticals Inc
20/10/201808:55PR Newswire (US)FDA approves asthsma indication for Dupixent® (dupilumab)NASDAQ:REGNRegeneron Pharmaceuticals Inc
19/10/201822:00PR Newswire (US)Kevzara® (sarilumab) Data at the 2018 ACR/ARHP Annual Meeting Provide Additional Insight on Safety and Efficacy in Rheumatoi...NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/10/201823:00PR Newswire (US)Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nas...NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/10/201816:44Dow Jones NewsSanofi's Dupixent Shows Positive Headline Results in Two Phase 3 StudiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/10/201815:59PR Newswire (US)Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nas...NASDAQ:REGNRegeneron Pharmaceuticals Inc
12/10/201822:47Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
09/10/201809:05PR Newswire (US)Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under InvestigationNASDAQ:REGNRegeneron Pharmaceuticals Inc
09/10/201800:30PR Newswire (US)Regeneron to Report Third Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on November 6, 20...NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/10/201806:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
29/09/201807:44Dow Jones NewsFDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell CarcinomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/09/201806:40PR Newswire (US)FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/09/201806:39PR Newswire (US)FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell CarcinomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/09/201806:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
26/09/201806:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
15/09/201815:59PR Newswire (US)Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Se...NASDAQ:REGNRegeneron Pharmaceuticals Inc
13/09/201821:00PR Newswire (US)FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic RetinopathyNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/09/201822:00PR Newswire (US)FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to redu...NASDAQ:REGNRegeneron Pharmaceuticals Inc
12/09/201814:59PR Newswire (US)FDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduc...NASDAQ:REGNRegeneron Pharmaceuticals Inc
12/09/201806:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
11/09/201807:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
01/09/201806:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
24/08/201823:30PR Newswire (US)Regeneron Announces Upcoming Investor Conference PresentationNASDAQ:REGNRegeneron Pharmaceuticals Inc
24/08/201806:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
22/08/201806:57Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
17/08/201821:00PR Newswire (US)FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular DegenerationNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/08/201822:06Dow Jones NewsRegeneron, Teva Report Positive Phase 3 Fasinumab ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN

Your Recent History

Delayed Upgrade Clock